Renaissance Technologies LLC Buys 1,375,000 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Renaissance Technologies LLC increased its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 204.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,046,600 shares of the company’s stock after acquiring an additional 1,375,000 shares during the period. Renaissance Technologies LLC owned about 0.90% of Gossamer Bio worth $1,844,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Gossamer Bio by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock worth $13,881,000 after buying an additional 128,150 shares during the period. Octagon Capital Advisors LP boosted its holdings in Gossamer Bio by 12.2% in the fourth quarter. Octagon Capital Advisors LP now owns 9,187,883 shares of the company’s stock valued at $8,384,000 after acquiring an additional 1,000,000 shares in the last quarter. Platinum Investment Management Ltd. boosted its holdings in Gossamer Bio by 29.8% in the fourth quarter. Platinum Investment Management Ltd. now owns 6,954,110 shares of the company’s stock valued at $6,346,000 after acquiring an additional 1,596,332 shares in the last quarter. Acadian Asset Management LLC increased its position in Gossamer Bio by 31.3% during the 2nd quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock valued at $3,235,000 after purchasing an additional 856,380 shares during the period. Finally, Monaco Asset Management SAM raised its holdings in Gossamer Bio by 390.3% in the 2nd quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock worth $2,456,000 after purchasing an additional 2,170,104 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Stock Performance

GOSS stock opened at $1.01 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.21 and a quick ratio of 8.21. Gossamer Bio, Inc. has a 1 year low of $0.45 and a 1 year high of $1.60. The company has a market cap of $228.48 million, a P/E ratio of -0.95 and a beta of 1.96. The stock’s fifty day moving average price is $0.91 and its 200-day moving average price is $0.89.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $95.84 million for the quarter, compared to analyst estimates of $160.00 million. On average, equities analysts forecast that Gossamer Bio, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GOSS. Oppenheimer started coverage on Gossamer Bio in a research report on Tuesday, June 25th. They set an “outperform” rating and a $9.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gossamer Bio in a research report on Monday, June 17th. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Tuesday, September 17th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Gossamer Bio currently has an average rating of “Buy” and an average price target of $9.20.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.